P&T COMMITTEE MEETING

Agenda July 9, 2019
1:00 p.m. – 5:00 p.m.

303 E. 17th Ave, 7th Floor Conference Rooms (7ABC), Denver, CO 80203

□ Committee Member Introductions

Unfinished Business and General Orders

- Approval of minutes from April 2, 2019 P&T meeting
- Update on Acne Agents
  - Topical
  - Oral Isotretinoin
  - Tetracyclines
- Update on Rosacea Agents, Topical
- Update on Non-Opioid Analgesics
- Update on Opioids, Long-Acting, Oral
- Update on Opioids, Short-Acting, Oral
- Update on Benign Prostatic Hypertrophy (BPH) Agents
- Update on Phosphate Binders
- Update on Respiratory Inhalants
  - Inhaled Anticholinergics & Anticholinergic Combinations
  - Inhaled Beta2 Agonists (short-acting)
  - Inhaled Beta2 Agonists (long-acting)
  - Inhaled Corticosteroids and Combinations
- Update on Androgenic Agents
  - Topical
  - Oral
  - Injectable
- Update on Mass review drug classes:
  - Update on Angiotensin Modulators/Angiotensin Modulator Combos
    - ACEIs & Combinations
    - ARBs & Combinations
    - Renin Antagonists & Combinations
  - Antihistamines, Newer Generation
  - Skeletal Muscle Relaxants
  - Topical Immunomodulators
New Business

1. Updates from the Prior Authorization Call Center

Drug Classes Up for Review:

- Review of Diabetes Management Classes – DPP-4 Inhibitors
- Review of Diabetes Management Classes – GLP-1 Analogues
- Review of Diabetes Management Classes – Hypoglycemic Combos
- Review of Diabetes Management Classes – SGLT-2 Inhibitors
- Review of Anticonvulsants
- Review of Colony Stimulating Factors
- Review of Erythropoiesis Stimulating Proteins
- Review of Hereditary Angioedema (HAE) Agents
- Review of Ophthalmic Immunomodulators
- Review of Anticoagulants
- Review of Contraceptives, Oral
- Review of GI Motility, Chronic
- Review of Stimulants and other ADHD Agents

Mass review drug classes:
- Bone Resorption Suppression and Related Agents
- Diabetes Management Classes – Amylin
- Diabetes Management Classes – Biguanides
- Diabetes Management Classes – Meglitinides
- Diabetes Management Classes – TZDs
- Overactive Bladder Agents
- Prenatal Vitamins

Each Review will contain:

- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share and FDA updates
- Committee Discussion and Recommendations for each Class

*Mass review drug classes will only include:

- Overview for each Drug Class, including market share and FDA updates

Upcoming Meeting Date: Tuesday, October 8; 1:00 p.m. – 5:00 p.m.

Presentations:

Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical information that will be presented for P&T Committee dissemination.

Please contact Brittany Schock, PDL Pharmacist, at 303-866-6371 or by email at brittany.schock@state.co.us to give advance notice to present at the meeting. Written
public comments can be submitted to Jessica Czechowski, Clinical Account Manager [jlczechowski@magellanhealth.com](mailto:jlczechowski@magellanhealth.com) (carbon copy Brittany Schock) and will be distributed to all present P&T Committee Members. Please provide public comments by July 5th, 2019 for dissemination to the P&T Committee. Refer to the Policies and Procedures document for requirements of Stakeholder comments.